-
ASCO China Perspective | Yanxia Zhao: TBCRC-053 Highlights the Promise of Neoadjuvant Radiotherapy Plus Immunotherapy in TNBC, Achieving ypN0 Rates of Up to 88.2%
Neoadjuvant immunotherapy combined with chemotherapy has become the standard of care for operable triple-negative breast cancer (TNBC), yet patients with high-risk features—particularly node-positive disease—continue to face a substantial risk of recurrence. To further improve outcomes, investigators are exploring whether adding radiotherapy during the neoadjuvant phase can enhance antitumor immunity.
-
ASCO China Perspective | Juliang Zhang: I-SPY 2.2 Highlights the Potential of Bispecific Immunotherapy Plus T-DXd and Novel Immune Subtyping in HER2-Negative Breast Cancer
Neoadjuvant treatment for operable HER2-negative breast cancer remains a major clinical challenge. The emergence of antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), is reshaping traditional treatment paradigms while raising new questions about patient selection and optimal therapeutic strategies.
-
ASCO China Perspective | Jin Yang: lidERA BC Suggests Oral SERDs Could Reshape Adjuvant Therapy for High-Risk Premenopausal Breast Cancer
At ASCO 2026, investigators presented the pre-specified menopausal subgroup analysis from the lidERA BC trial. Compared with standard endocrine therapy, the oral selective estrogen receptor degrader (SERD) giredestrant reduced the risk of distant recurrence by 42% in premenopausal women with HR+/HER2− early breast cancer (HR=0.58), while also reducing the risk by 24% in postmenopausal patients…
-
ASCO China Voice | Zhenzhen Liu: HELEN Series Studies Presented at ASCO Advance Precision Treatment Strategies for Breast Cancer
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Zhenzhen Liu and colleagues from Henan Cancer Hospital presented four studies from the HELEN clinical research program (Abstracts #1009, #509, #1054, and #609), spanning key breast cancer subtypes including triple-negative breast cancer (TNBC), HER2-positive disease, and HR+/HER2+ breast cancer.
-
ASCO China Voice | Xiaowei Qi: Pembrolizumab-Free Anthracycline-Sparing Neoadjuvant Regimen with Penpulimab, Taxane, and Carboplatin Demonstrates Promising Efficacy and Safety in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive disease with a poor prognosis, making it essential to improve the efficacy of neoadjuvant therapy while minimizing treatment-related toxicity. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Xiaowei Qi and colleagues from Southwest Hospital, Army Medical University presented the latest results from the NeoTAPPL study…
-
ASCO China Voice | Zhimin Shao and Zhonghua Wang’s Team: IRIS-A Study Demonstrates That Capecitabine Plus Trastuzumab Provides Effective, Low-Toxicity De-escalated Adjuvant Therapy for Stage IA HER2-Positive Breast Cancer
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 29 to June 2 in Chicago, USA, results from the IRIS-A study (Abstract #508) were presented during the Rapid Oral Abstract Session on Local, Regional, and Adjuvant Breast Cancer.
-
ASCO China Voice | Jiong Wu: PANKU-Breast02 Meets Both PFS and OS Primary Endpoints, with Iza-Bren Delivering a New Breakthrough for Previously Treated Advanced Triple-Negative Breast Cancer
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Jiong Wu from Fudan University Shanghai Cancer Center presented the highly anticipated PANKU-Breast02 study (Abstract LBA1003).
-
ASCO China Voice | Professor Hui Xie: BMI May Serve as a Simple Stratification Marker for Trastuzumab Deruxtecan in Advanced Breast Cancer
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, a study led by Professor Hui Xie from Jiangsu Cancer Hospital was presented as an electronic poster (Abstract e13078). Using multicenter real-world data from China, the study is the first to systematically evaluate the relationship between body mass index (BMI) and the efficacy and…
Connecting Medical Expertise through Media